Home > Publications Database > Treatment for Alzheimer's disease. > print

001     281511
005     20251102002049.0
024 7 _ |a 10.1016/S0140-6736(25)01329-7
|2 doi
024 7 _ |a pmid:40997839
|2 pmid
024 7 _ |a 0140-6736
|2 ISSN
024 7 _ |a 0023-7507
|2 ISSN
024 7 _ |a 1474-547X
|2 ISSN
024 7 _ |a altmetric:181615419
|2 altmetric
037 _ _ |a DZNE-2025-01132
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Fox, Nick C
|b 0
245 _ _ |a Treatment for Alzheimer's disease.
260 _ _ |a London [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1761731814_30625
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Over the last three decades, the evidence on how to best treat the cognitive and non-cognitive symptoms of patients with Alzheimer's disease has increased. Although these pharmacological and non-pharmacological strategies have significantly improved health outcomes for patients with Alzheimer's disease, many lack stringent evidence of efficacy. In this second paper of the Series, we provide practical and realistic advice on how to prioritise pharmacological and non-pharmacological strategies to ameliorate cognitive impairment and behavioural and psychological symptoms of dementia. In this clinical environment, dementia specialists are faced with the challenge of holistically integrating the much anticipated and, in some respects, controversial anti-β amyloid monoclonal antibodies. Here, we present the current approval scenario of monoclonal antibodies, our view on how they might further contribute to improve patients' quality of life, and how they could be seamlessly integrated with existing best care options.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Antibodies, Monoclonal
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Antibodies, Monoclonal, Humanized
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: drug therapy
|2 MeSH
650 _ 2 |a Alzheimer Disease: therapy
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal: therapeutic use
|2 MeSH
650 _ 2 |a Quality of Life
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: immunology
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: therapeutic use
|2 MeSH
700 1 _ |a Belder, Christopher
|b 1
700 1 _ |a Ballard, Clive
|b 2
700 1 _ |a Kales, Helen C
|b 3
700 1 _ |a Mummery, Catherine
|b 4
700 1 _ |a Caramelli, Paulo
|b 5
700 1 _ |a Ciccarelli, Olga
|b 6
700 1 _ |a Frederiksen, Kristian S
|b 7
700 1 _ |a Gomez-Isla, Teresa
|b 8
700 1 _ |a Ismail, Zahinoor
|b 9
700 1 _ |a Paquet, Claire
|b 10
700 1 _ |a Petersen, Ronald C
|b 11
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 12
|u dzne
700 1 _ |a Robinson, Louise
|b 13
700 1 _ |a Sayin, Ozge
|b 14
700 1 _ |a Frisoni, Giovanni B
|b 15
773 _ _ |a 10.1016/S0140-6736(25)01329-7
|g Vol. 406, no. 10510, p. 1408 - 1423
|0 PERI:(DE-600)1476593-7
|n 10510
|p 1408 - 1423
|t The lancet
|v 406
|y 2025
|x 0140-6736
856 4 _ |u https://pub.dzne.de/record/281511/files/DZNE-2025-01132%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281511/files/DZNE-2025-01132.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281511/files/DZNE-2025-01132.pdf?subformat=pdfa
856 4 _ |x pdfa
|u https://pub.dzne.de/record/281511/files/DZNE-2025-01132%20SUP.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281511
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2812234
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a IF >= 90
|0 StatID:(DE-HGF)9990
|2 StatID
|b LANCET : 2022
|d 2024-12-16
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000022
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21